

**Freedom of Information Act 2000 - Request Reference Fol/20/357**

**Treatment**

**Request details**

**1. How many patients have been treated with the following drugs (for any disease) in the past 6 months:**

- Ampyra (dalfampridine) **0**
- Aubagio (teriflunomide) **1**
- Avonex (interferon beta-1a) **0**
- Betaferon (interferon beta-1b) **0**
- Brabio (glatiramer acetate) **4**
- · Copaxone (glatiramer acetate) **0**
- · Extavia (beta interferon-1b) **0**
- · Gilenya (fingolimod) **50**
- · Lemtrada (alemtuzumab) **9**
- Mavenclad (cladribine) **3**
- Mayzent (siponimod) **0**
- Ocrevus (ocrelizumab) **78**
- Plegridy (peginterferon beta-1a) **0**
- · Rebif (beta interferon-1a) **8**
- · Tecfidera (dimethyl fumarate) **120**
- · Tysabri (natalizumab) **78**
- Vumerity (diroximel fumarate) **0**
- Zeposia (ozanimod) **0**

**2. How many patients have been treated in the past 6 months for the following types of multiple sclerosis:**

- Relapsing remitting MS (RRMS)
- Secondary progressive MS (SPMS)
- Primary progressive MS (PPMS)
- Multiple Sclerosis - any type

Please note the UHB can only identify patients with an MS (non-specified) diagnosis admitted to hospital.

**Distinct CRN by Month**

| CRN Count | 2020 |     |     |     |     |     |
|-----------|------|-----|-----|-----|-----|-----|
|           | APR  | MAY | JUN | JUL | AUG | SEP |
| G35X      | 45   | 76  | 96  | 95  | 92  | 98  |

**Distinct CRN for report**

|      | CRN Count Total |
|------|-----------------|
| G35X | 230             |